NSE: ROSSARI | BSE: 543213

Slowing Down Stock

Download real time

681.40 7.50 (1.11%)

29.95% Fall from 52W High

18,081 NSE+BSE Volume

NSE 26 Jun, 2025 10:38 AM (IST)

3,772.7

Market Cap

Below industry Median

0.7

Beta 1Year

Very Low volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Search Inside the pdf :

Rossari Biotech Ltd.

05 May 2025

681.40

1.11%

Additional capacities to drive top-line

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Revenue came in at INR 5,796 Mn, up 22.6% YoY (+13.0% QoQ), driven by robust demand for the HPPC segment. Q4FY25 revenue came broadly in line with our estimates.

Rossari Biotech Ltd.'s price crossed above 50Day SMA today

Rossari Biotech Ltd.

24 Jan 2025

681.40

1.11%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

•Rossari reported slightly lower-than-expected revenue but achieved 11% YoY growth, driven by strong execution in export markets for HPPC and textile segments, along with healthy performance in key ANH markets, despite challenging domestic conditions.
•Despite delivering lower than expected revenue, gross profit grew 16% YoY, aided by new product launches in Buzil Rossari Business.

Rossari Biotech Ltd. is trading below its 150 day SMA of 710.2

Rossari Biotech Ltd.

23 Oct 2024

681.40

1.11%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech reported lower than expected topline and bottom line Q2FY25 due to softer HPPC growth and material weakness in TSC segment. Despite these pressures , it posted 3.1%/12%/3.2%/7.2% revenue /GP/EBITDA/PAT growth on YOY basis led by heathy export growth in the HPPC segment.

Rossari Biotech Ltd. is trading above its 100 day SMA of 665.0

Rossari Biotech Ltd.

22 Oct 2024

681.40

1.11%

HPPC steady; outlook bright backed by capex, market gain; Buy

Buy: Rossari Biotech Ltd.

Target

Anand Rathi

We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.

Rossari Biotech Ltd. has an average target of 924.25 from 4 brokers.

Rossari Biotech Ltd.

22 Oct 2024

681.40

1.11%

Rossari Biotech | Q2FY25 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd.'s price crossed above 30Day SMA today

Rossari Biotech Ltd.

21 Oct 2024

681.40

1.11%

Exports drive revenue growth

Hold: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY25 HPPC revenue growth (+6.2% YoY) was hurt from softer demand and restricted ethylene oxide (EO) capacity.

Rossari Biotech Ltd.'s price crossed above 50Day SMA today

Rossari Biotech Ltd.

24 Jul 2024

681.40

1.11%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech’s revenue beat our estimate (+2.8%) due to strong volume growth in HPPC (Home, Personal Care, and Performance Chemicals) business and in the TSC (Textile Specialty Chemicals) division.
We anticipate this growth momentum in revenue will continue due to strong demand in the end customer segments.

Rossari Biotech Ltd.'s price crossed above 30Day SMA today

Rossari Biotech Ltd.

13 Jun 2024

681.40

1.11%

Diversified business mix; no major China competition; initiating, with a Buy

Buy: Rossari Biotech Ltd.

Anand Rathi

Rossari Biotech is a leading specialty chemicals manufacturing company, focusing on four core chemistries of enzymes, silicones, acrylics and surfactants. It caters to industries such as home and personal care, and performance chemicals (HPPC), textile specialty chemicals (TSC) and animal health and nutrition (AHN) products

Rossari Biotech Ltd.'s price crossed above 30Day SMA today

Rossari Biotech Ltd.

08 May 2024

681.40

1.11%

Strong growth in HPPC segment drives the performance

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech missed our revenue estimate due to subdued growth In Textile Specialty Chemical segment and Animal Health Nutrition segment which was partially offset by growth in Home, Personal care and Performance chemicals (HPPC) segment.
The stock is trading at PE multiples of 23.3x/18.9x based on FY25E/FY26E EPS estimates, respectively.